Evident from the EQUATOR trial, “the psoriatic arthritis treatment with filgotinib shows considerable rectifications in psoriasis, enthesitis, and peripheral arthritis.” The trial involved a total of 191 patients with active moderate-to-severe psoriatic arthritis from 25 places in seven countries.

These patients showed no response against at least one csDMARD (one conventional synthetic disease-modifying anti-rheumatic drug) and the uptake of that DMARD was continued throughout the analysis, if the patients obtained this treatment for 12 weeks before screening. Afterwards, they were on a stable dose for approximately four weeks prior to baseline. Further, the patients obtaining 20% improvements in ACR20 (American College of Rheumatology response criteria) at week 16 was considered as the major endpoint of the analysis.

The major endpoint noticed in 80% of patients from filgotinib group and 33% of placebo group. The most common side effects that noticed in both groups were headache and nasopharyngitis. There was one treatment-emergent adverse effect also found in the patients of both groups. Regarding safety, no new data was detected. Overall, this JAK1 inhibition shows significant better overall psoriatic arthritis disease control.